gilead sciences inc lakeside drive foster city california gilead sciences annual report f wwwgileadcom gilead sciences annual report gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need companys mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california gilead operations north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead sciences gilead logo design hepsera letairis ranexa stribild truvada viread vistide volibris registered trademarks gilead sciences inc one related companies atripla registered trademark bristolmyers squibb gilead sciences llc lexiscan registered trademark astellas us llc tamiflu registered trademark hoffmannla roche inc macugen registered trademark eyetech inc full us prescribing information gilead products available wwwgileadcomwe inspired opportunity address unmet medical needs patients lifethreatening diseases around world nosellot ngised welcome gilead cover katie living hiv since infant growing maryland faced stigma young age disease despite experience maintains positive outlook life credits supportive family friends knows firsthand importance support people facing serious health challenges katie plans devote career helping need recently graduated university central florida aims pursue masters degree public health dedication stribild approved hiv effectiveness safety profiles convenience single tablet regimens become standard care hiv single hivaids tablet regimen combining multiple drugs required hiv treatment helps ensure patients take medicine avoiding partial doses lead resistance therapy end achieved turning significant milestone approval us food drug administration fda stribild fixeddose formulation four gilead medicines oncedaily pill point treatmentnave patients third single tablet regimen hiv joining atripla complera among prescribed antiretroviral regimens united states europe stribild new tools hiv prevention july truvada became first product approved fda combination safer sex practices reduce risk hiv uninfected adults high risk strategy called preexposure prophylaxis prep international aids conferencethe largest gathering scientists clinicians public health experts advocates committed eradicating diseasea sense growing optimism prevailed approval truvada prep noted milestone could help slow spread hiv communities greatest risk offering new hope bringing epidemic control great progress diagnosis linkage care individuals hiv occurred last several years hiv prevention remains challenge around world jamie diagnosed hiv order cope fear experienced time diagnosis jamie educated extensively disease worked closely doctor find right treatment doctors encouragement began antiretroviral therapy right away today among many interests jamie maintains passion travel outdoorsrecently visiting small fishing village mexico patagonia innovation transforming treatment paradigms current interferonbased regimens available treating hepatitis c remain new treatment challenge patients due safety issues side effects variable response rates burdensome injections gilead advancing development oral hepatitis c medicines goal options improving tolerability convenience increasing cure rates november reported percent sustained virologic response rate svr treatmentnave chronic genotype hepatitis c patients enrolled phase trial evaluating alloral combination sofosbuvir gs ledipasvir gs ribavirin based data sofosbuvir ledipasvir hepatitis c coformulated single pill studied phase trials sofosbuvir accelerating clinical development following acquisition pharmasset january moved quickly expand clinical testing hepatitis c therapies phase trials exploring sofosbuvir various combinations agents genotype patient populations ongoing new studies initiated enrolling participants patient provider interest able complete enrollment trials within weeks addition evaluating multiple hepatitis c drug combinations diverse genotypes patient populations investigating ways shorten therapy one year matter weeks edward gane md professor medicine university auckland new zealand leading expert treating chronic hepatitis c principal investigator electron study gileads investigational agent sofosbuvir dr gane excited potential alloral regimens could make treatment effective tolerable patients hcv rna undetectable four weeks completing therapy excellence insights molecular biology scientific understanding biological mechanisms underlying cancer rapidly increasingand understanding seeking leading potential breakthroughs therapy one area focus gilead involves investigational new agents specifically target intracellular signaling pathways responsible tumor growth another improve approach involves targeting extracellular matrix supports system helps enable solid tumor growth importantly certain targeted agents may fewer side treatment effects conventional treatments chemotherapy chronic lymphocytic leukemia cancer image colors modified improving patient outcomes gilead developing new treatment options may target range cancers also exploring utility medications used combination therapy diseases among difficult treat work informed robust understanding biology focuses interrupting key pathways involved formation replication cancerous cells tessa st rose clinical research coordinator stanford university helps people serious blood cancers enroll research studies investigational therapies driven potential help patients families critical time sees role essential bridge patients oftencomplex clinical trial process tessa works closely patients answer questions explain research protocols schedule study visitsall important steps search find new treatments today future stockholders employees friends exceptional year gilead lives lost international aids conference efficacy viread dose times sciences company achieved revenues washington dc july new optimism lower could help improve tolerability billion including product sales emerged fueled improvements hiv pre therapy interim findings ongoing billion delivered medicines vention diagnosis care around world phase study showed tafcontaining record number people serious diseases single tablet regimen achieved similar around world importantly significant gilead remains forefront advancing virologic response stribild early progress made advancing rd programs hiv treatment development initiated first phase study evaluating across therapeutic areas new single tablet regimens august taf part single tablet regimen us food drug administration fda june marked th anniversary approved stribild companys third single july us fda approved truvada gileads founding company grown tablet regimen stribild combines four medi preexposure prophylaxis prepmarking rapidly biotech startup multi cations complete hiv treatment regimen first time product approved national biopharmaceutical company oncedaily pill approach helps allow reducing risk hiv infection highrisk employees spanning countries patients adhere fully suppressive adults combination safer sex practices four continents organization inspired course therapy easily consis key advancement fight hiv opportunity address needs tently critical successful result decades work involving patients involved improving management disease commercial investigators academic medical institutions patient care patients like katie cover organization introduced product imme funding agencies jamie physicians like edward gane diately following approval stribild clinical trial participants around world left right gregg h alton executive vice president corporate medical affairs kevin young cbe executive vice president healthcare providers along atripla complera achieved commercial operations robin l washington senior vice president chief financial officer john c martin phd chairman tessa st rose close billion product sales addition clinical interventions chief executive officer norbert w bischofberger phd executive vice president research development chief scientific prep gilead continued support educa officer katie l watson senior vice president human resources john f milligan phd president chief operating officer hivaids longterm goal ensure hiv tion outreach increase access hiv patients working prescribers testing care worldwide partners scientific advancementsin drug design option choose single tablet regimen conducted hiv tests formulation deliveryand public health may right important progress represents important contribution advancementsin disease awareness screen made development program public health helping diagnose infected ing linkage carecollectively tenofovir alafenamide taf gs individuals connect care stemmed global hivaids epidemic nucleotide reverse transcriptase inhibitor november us preventive services remarkable statement make years taf may able exhibit greater antiviral task force recommended routine hiv testing aids pandemic million adolescents adults ages participants n remaining hcv rna unde diabetes addition new generation late area oncology company increasing access closing require private insurers cover cost tectable four weeks completing therapy sodium current inhibitors developed advancing novel therapies target many patients around globe summary organization strong screening svr phase trials exploring sofosbuvir gs currently phase key molecular signaling pathways resources obtain medi business foundation billion various combinations genotype patient studies potential treat ischemic extracellular matrix involved growth cines need work expand treatment revenues continue make liver diseases populations ongoing initial regulatory heart disease arrhythmias area survival certain cancers exist access wherever possible companys significant progress advancing new thera filings expected first half pulmonary arterial hypertension pah ing treatment options limited idelalisib pharmasset acquisition completed comprehensive patient assistance programs pies solidify future growth appropriate commercial infrastructure phase research program designed gs pik delta inhibitor currently january leadership position provide medicines united states assembled support potential advance understanding disease evaluated phase studies indo established drug development cost lowincome uninsured patients would like thank employees launch sofosbuvir pathology define clinical profile lent nonhodgkins lymphoma chronic chronic hepatitis c virus hcv infection copay assistance coupon programs commitment excellence hard work letairis including potential lymphocytic leukemia simtuzumab also last year advanced nucleo help unable afford copayments also would like acknowledge invaluable also liver meeting sixyear clinical trial product used combination another progressing phase studies assess tide nsb inhibitor sofosbuvir gs associated commercial health insurance input board directors data viread treatment chronic oral pah treatment frontline therapy safety efficacy treating pancreatic oncedaily fixeddose combination tablet programs hepatitis b virus hbv infection present colorectal cancer myelofibrosis containing sofosbuvir nsa inhibitor thank continued support ed showed sustained virological area respiratory disease cayston certain fibrotic diseases recent com ledipasvir gs phase testing gilead also expanding access look forward year aheadand biochemical responses among patients inhaled antibiotic approved treat cystic pletion ym biosciences acquisition goal transform paradigm hcv care medications resourcelimited parts progress believe make many evidence viral resistance results fibrosis cf patients pseudomonas selective jak inhibitor momelotinib gs developing alloral treatment regimen worldincluding developing countries patients around world reinforce viread position mostpre aeruginosa evaluated phase cyt added growing oncology higher cure rates better tolerability hivaids epidemic affecting millions scribed medicine chronic hbv united studies assess efficacy treating inflammation pipeline phase study greater convenience patients people december approximately states european countries bacterial infections associated noncf momelotinib myelofibrosis planned currently available options million patients developing world bronchiectasis results trials second half receiving one gileads hiv medicines expected november first data showing cardiovascular respiratory doubling number patients john c martin phd efficacy sofosbuvir ledipasvir plus riba oncologyinflammation reached since chairman chief executive officer addition evaluating gs virin presented liver meeting across therapeutic areas look ways phase clinical trials compound annual conference american associa appropriately expand use available shown preclinical studies block respiratory tion study liver diseases interim medicines advance investigational syncytial virus rsv rsv pathogen results phase study suggested therapies address unmet needs infects human respiratory tract leading week course medicines patients patients cardiovascular disease ranexa forwardlooking statement infected genotype hcvthe com bronchiolitis pneumonia estimated annual report includes forwardlooking statements regarding clinical studies product candidates including anticipated timing achievement certain oral late sodium current inhibitor newborns hospitalized development milestones regulatory filings launches statements predictions involve risks uncertainties actual results may differ materially please mon strain united states currently indicated chronic angina also refer gileads annual report year ended december attached report risks uncertainties affecting gileads business gilead disclaims rsv every year united states difficult treatresulted percent explored phase studies type obligation update forwardlooking statements report financial focus area highlights hivaids product sales total revenues gilead working develop next generation hiv millions millions single tablet regimens effective tolerable convenient may provide certain advantages existing treatment options particularly important individuals hiv diagnosed brought care lifelong treatment required control virus conducting clinical trials tenofovir alafen amide taf gs taf may able exhibit greater antiviral efficacy viread dose times lower may improve tolerability hiv therapy phase studies examine oncedaily single tablet regimen taf emtriva integrase inhibitor elvitegravir boosting agent cobicistat compared stribild among patients new hiv therapy ambisome ranexa letairis hiv medicines reduce level virus antiviral franchise blood undetectable levels ultimate goal develop cure gilead scientists engaged early stage research identify novel therapeutic agents may help eradicate hiv infection earnings per share operating cash flow eu marketing approval submitted millions stribild elvitegravir mgcobicistat mg emtricitabine mgtenofovir disoproxil fumarate mg potential indication hivaids us eu marketing approvals submitted cobicistat pharmacokinetic enhancer potential indication hivaids elvitegravir integrase inhibitor potential indication hivaids earnings per share calculations phase periods presented reflect twoforone stock single tablet regimen elvitegravircobicistat split effective january emtricitabinetenofovir alafenamide nongaap diluted earnings per share potential indication hivaids exclude impact aftertax acquisition related expenses restructuring phase expenses stockbased single tablet regimen darunavircobicistat compensation expenses emtricitabinetenofovir alafenamide nongaap diluted earnings per share potential indication hivaids gaap diluted exclude aftertax acquisitionrelated expenses earnings per share stockbased compensation n eao rn ng ina ga sp pd eil ru st hed ar e expenses nongaap diluted earnings per share exclude aftertax acquisitionrelated expenses restructuring expenses stockbased compensation expenses roberto tascione general manager italy gilead sciences focus area focus area liver diseases cardiovascular disease chronic hepatitis b c caused persistent viral cardiovascular disease diabetes represent infections frequently lead liver cirrhosis liver considerable public health burden worldwide failure cancer significant unmet medical need new therapeutic options patients living conditions chronic hepatitis b treated using viread one ongoing clinical study showed regression number clinical studies ongoing explore cirrhosis five years therapy approximately uses ranexa currently indicated treatment percent patients baseline liver biopsy data chronic angina may potentially benefit specific available patients chronic hepati populations patients includes study evaluating tis b lifelong antiviral therapy required ranexa patients chronic angina type continue research combination approaches diabetes additional clinical trials evaluating ranexa increase cure rates chronic hepatitis b patients patients unable control type diabetes including oral medicines therapeutic vaccines currently available medications patients undergone stenting procedures gilead also advancing broad diverse pipeline investigational treatments chronic hepatitis c working identify potential new therapies ultimate goal developing alloral regimen cardiovascular disease exploring mechanism works across strains virus results action underlying ranexainhibition late sodium high cure rates shorter treatment duration current research led us phase clinical todays therapies completed four phase study evaluating ranexa combination drone studies sofosbuvir gs single agent admin darone paroxysmal atrial fibrillation identify istered standard care therapies positive results novel molecule gs may potential trials announced late early chronic hepatitis c phase treat various cardiovascular diseases ischemic support initial regulatory applications phase ranolazine late sodium current inhibitor heart disease arrhythmias sofosbuvir nucleotide nsb inhibitor potential indication incomplete compound additionally developed single tablet regimen sofosbuvir ledipasvir revascularization postpci even advancements pulmonary arterial oncedaily fixeddose combination sofosbuvir nucleotide nsb inhibitornsa inhibitor ranolazine late sodium current inhibitor potential indication type diabetes hypertension treatments letairis ledipasvir gs phase studies phase gs ns protease inhibitor phase need optimize use existing agents people living chronic hepatitis c often gs nonnucleoside nsb inhibitor ranolazinedronedarone fixeddose gilead continues conduct phase gs pangenotypic nsa inhibitor combination viral diseases including hiv many patients studies answer questions optimal patient care potential indication paroxysmal atrial await liver transplantation phase fibrillation define clinical benefit letairis gs tlr agonist also evaluating hepatitis c treatments diverse phase broader patient populations difficulttotreat patient groups chronic hepatitis b gs potential indications ischemic heart disease phase gs tlr agonist arrhythmias tenofovir alafenamide nucleotide reverse transcriptase inhibitor liver fibrosis due nonalcoholic steatohepatitis primary sclerosing cholangitis diana brainard md senior director clinical research liver phase rico calara phd associate director medical sciences diseases gilead sciences simtuzumab monoclonal antibody gilead sciences phil pang md director clinical research liver diseases formerly gs janelle goins pharmd associate director medical sciences gilead sciences gilead sciences focus area focus area respiratory oncology disease inflammation gileads first product category respiratory oncology inflammation newer focus areas disease tamiflu remains leading antiviral gilead making rapid progress identifying treatment prevention seasonal influenza targeted investigational cancer therapies evaluating clinical studies inhaled antibiotic cayston indicated treat respiratory pseudomonas aeruginosa people lead oncology candidates include idelalisib gs cystic fibrosis cf inherited disease affects momelotinib gscyt idelalisib lungs digestive system also investigating small molecule drug designed inhibit pik potential cayston treat bacterial infections delta signaling pathway thought drive certain people noncf bronchiectasis cancer cell development compound stud ied clinical trials chronic lymphocytic leukemia simtuzumab gs monoclonal antibody indolent nonhodgkins lymphoma momelotinib investigated potential treatment idiopathic investigational jak inhibitor shown promise pulmonary fibrosis lifethreatening scarring treatment myelofibrosis blood disorder lungs known cause gs studied molecule added gileads development pipeline respiratory syncytial virus rsv infects acquisition ym biosciences human respiratory tract lead bronchiolitis pneumonia rsv common microbial simtuzumab gs first monoclonal antibody cause lung airway infections infants developed target loxl enzyme thought young children involved solid tumor growth studied pancreatic colorectal cancers myelofibrosis addition gs syk inhibitor clinical phase phase studies bcell malignancies aztreonam inhalation solution idelalisib pik delta inhibitor potential indication noncf bronchiectasis potential indication chronic lymphocytic partnerships exploring new therapeutic leukemia phase targets oncology multiyear collaboration simtuzumab monoclonal antibody idelalisib pik delta inhibitor potential indication idiopathic pulmonary potential indication indolent nonhodgkins yale school medicine searching genetic fibrosis lymphoma basis underlying molecular mechanisms many gs phase forms cancer potential indication respiratory syncytial momelotinib jak inhibitor virus potential indication myelofibrosis simtuzumab monoclonal antibody potential indication myelofibrosis simtuzumab monoclonal antibody potential indication pancreatic cancer simtuzumab monoclonal antibody potential indication colorectal cancer gs pik delta inhibitor potential indication lymphoid malignancies phase gs syk inhibitor derek marshall research scientist biology gilead sciences potential indication bcell malignancies vivian barry associate scientist biology gilead sciences developed single agent combination idelalisib rhyannon spangler senior research associate biology anne mathew director marketing gilead sciences gilead sciences focus area marketed access treatment products hivaids liver disease respiratory atripla hepsera advancing therapies lifethreatening diseases efavirenz mgemtricitabine adefovir dipivoxil cayston requires innovationnot laboratory also mgtenofovir disoproxil chronic hepatitis b aztreonam inhalation solution fumarate mg medicines delivered patients make glaxosmithkline inc cystic fibrosis p aeruginosa priority ensure people need therapies hivaids china japan saudi arabia bristolmyers squibb company access regardless ability pay us western europe canada live world merck co inc rest world tamiflu oseltamivir phosphate ensuring access developing world countries viread many diseases medicines treat place tenofovir disoproxil fumarate influenza b complera chronic hepatitis b f hoffmannla roche ltd greatest burden developing world countries worldwide emtricitabinerilpivirinetenofovir japan tobacco inc japan fewest resources address challenge gilead disoproxil fumarate works manufacturers regional hivaids local distributors generic licensees lower prices janssen rd ireland marketed eviplera europe cardiovascular enable generic production certain gilead medi cines hivaids chronic hepatitis b began transferring technology stribild emtriva newest hiv single tablet regimen partners emtricitabine begin process producing generic versions hivaids patients low middleincome countries also japan tobacco inc japan letairis ambisome coordinate support educational activities medi ambrisentan amphotericin b liposome cal clinical workers ensure proper use pulmonary arterial hypertension injection medicines group severe fungal infections access highlights stribild glaxosmithkline inc astellas pharma inc us canada also marked first year fiveyear expanded three half million hiv patients low elvitegravir mgcobicistat mg marketed volibris outside us dainippon sumitomo pharma co ltd partnership world health organization middleincome countries receiving gilead emtricitabine mgtenofovir japan disoproxil fumarate mg therapiesrepresenting approximately onethird control visceral leishmaniasis vl seconddeadliest people treated hiv countries hivaids lexiscan parasitic disease malaria gilead provide japan tobacco inc japan regadenoson injection enough ambisome treat patients vl indian manufacturers one south african coronary vasodilation macugen manufacturer licensed produce pegaptanib sodium injection astellas pharma inc us canada ensuring access united states generic versions hiv chronic hepatitis b rapidscan europe select ther neovascular wet agerelated macular recognizing financial difficulties many americans medicines developing countries truvada markets degeneration face todays economy gilead established one half people united states taking emtricitabinetenofovir eyetech inc us gilead hiv medicines receive federal disoproxil fumarate pfizer inc outside us comprehensive packages patient assis state programs substantially discounted hivaids tance solutions includes providing medicines prices japan tobacco inc japan eligible patients charge offering copay ranexa ranolazine coupon program patients private insurance regardless income also long history chronic angina vistide viread menarini group europe cidofovir injection working state aids drug assistance programs tenofovir disoproxil fumarate cmv retinitis patients aids adaps increase access hiv treatment voluntary hivaids price freeze additional discounts adaps japan tobacco inc japan hiv medicines run images shown represent actual size corporate gilead sciences inc lakeside drive information foster city california gilead sciences annual report f wwwgileadcom board directors senior leadership team robert schooley md transfer agent registrar john c martin phd john c martin phd professor medicine head communications concerning stock chairman chief executive officer chairman chief executive officer division infectious diseases transfer requirements lost certificates gilead sciences vice chair department medicine changes address john f milligan phd university california san diego directed transfer agent james denny president chief operating officer lead independent director eric j topol md computershare gilead sciences board directors norbert w bischofberger phd director scripps translational washington boulevard executive vice president science institute jersey city nj john f cogan phd research development chief academic officer scripps health usa senior fellow hoover institution chief scientific officer professor genomics stanford university scripps research institute wwwcomputersharecom gregg h alton etienne f davignon executive vice president bernard wagner md equal opportunity employer minister state corporate medical affairs emeritus research professor gilead sciences proud equal chairman genfina pathology new york university opportunity employer extends kevin young cbe medical center employment men women carla hills executive vice president culturally diverse backgrounds chair chief executive officer commercial operations corporate secretary environment respects individual hills company international gregg h alton differences recognizes employee consultants robin l washington executive vice president corporate integral member company senior vice president medical affairs workforce reflects values kevin e lofton chief financial officer celebrates individuals make president chief executive officer independent registered public growing team catholic health initiatives katie l watson accountants senior vice president ernst young llp john w madigan human resources palo alto california retired chairman chief executive officer scientific advisory board corporate headquarters tribune company joel r huff phd chairperson gilead sciences inc retired vice president lakeside drive gordon e moore phd medicinal chemistry foster city ca usa retired chairman merck research laboratories chief executive officer wwwgileadcom intel corporation paul berg phd cahill professor stockholder inquiries nicholas g moore biochemistry emeritus inquiries stockholders retired global chairman stanford university school medicine potential investors regarding company pricewaterhousecoopers always welcome receive francis v chisari md prompt response please direct richard j whitley md professor virology immunology requests information distinguished professor scripps research institute loeb scholar chair pediatrics investor relations professor pediatrics microbiology peter b dervan phd gilead sciences inc medicine neurosurgery bren professor chemistry lakeside drive university alabama birmingham california institute technology foster city ca usa gayle edlund wilson paul e klotman md former chair ralph parsons president chief executive officer information regarding gilead also foundation john e clara b whitmore available wwwgileadcom professor baylor college medicine per woldolsen stock listing retired president human health john w mellors md gilead common stock traded intercontinental division professor medicine nasdaq global select stock market merck co inc chief division infectious diseases symbol gild university pittsburgh school director emeritus gilead sciences medicine annual meeting board directors annual meeting stockholders george p shultz phd eugene r schiff md held wednesday distinguished fellow leonard miller professor medicine may westin san francisco hoover institution director schiff liver institute airport hotel stanford university director center liver diseases university miami school medicine gilead sciences annual report gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need companys mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california gilead operations north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead sciences gilead logo design hepsera letairis ranexa stribild truvada viread vistide volibris registered trademarks gilead sciences inc one related companies atripla registered trademark bristolmyers squibb gilead sciences llc lexiscan registered trademark astellas us llc tamiflu registered trademark hoffmannla roche inc macugen registered trademark eyetech inc full us prescribing information gilead products available wwwgileadcom gilead sciences inc lakeside drive foster city california gilead sciences annual report f wwwgileadcom gilead sciences annual report gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need companys mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california gilead operations north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead sciences gilead logo design hepsera letairis ranexa stribild truvada viread vistide volibris registered trademarks gilead sciences inc one related companies atripla registered trademark bristolmyers squibb gilead sciences llc lexiscan registered trademark astellas us llc tamiflu registered trademark hoffmannla roche inc macugen registered trademark eyetech inc full us prescribing information gilead products available wwwgileadcom